At the 2023 Bio-欧洲 Spring, RudaCure was represented by CEO Yongho Kim and Research Strategy Team Leader Hawon Jeon, who held a meeting with Ceva, a French company currently exploring 联合开发 of RCI001 for 兽用 medicine.
The meeting provided an opportunity to discuss future joint commercialization directions with Ceva representatives and to exchange information that both companies need to share.
Many companies showed interest in RCI001 for 干眼症 and productive discussions were held. For RCI002, the 疼痛治疗药, Italian company Dompe and the long-established German company Grünenthal expressed interest and agreed to continue discussions on the drug.
